S&P/ASX 200 (XJO) morning report, ASX 200 futures lower
James Dunn
January 19, 2023
The S&P/ASX 200 (INDEXASX: XJO) is expected to open lower
CSL Limited (ASX: CSL) is Australia’s largest (and some might say best) healthcare company, specialising in biopharmaceuticals. Founded in the late 1900s as the Commonwealth Serum Laboratories, CSL was sold by the Australian Government to Australian investors via the share market in 1994 at $2.30 per share, at which time it doubled its size through an international acquisition. CSL is a global leader in blood plasma vaccines (think: the flu) and antivenoms, providing relief for potentially life-threatening medical conditions.
The S&P/ASX 200 (INDEXASX: XJO) is expected to open lower
Get some top ASX share ideas for 2023. Wesfarmers Ltd
The CSL Limited (ASX:CSL) share price is down after it
Danielle Ecuyer of Shareplicity joins Owen Rask and Kate Campbell
The S&P/ASX 200 (INDEXASX: XJO) managed a small gain on
The CSL Limited (ASX: CSL) share price is in focus
Nathan Bell, CFA is Head of Portfolio Management at The
Drew Meredith, CFP and Owen Rask are back on The
The CSL Limited (ASX:CSL) share price is in focus after
Want to level-up your analytical skills and investing insights but don’t know where to start? Join 50,000 Australian investors on our mailing list and we’ll send you our favourite podcasts, courses, resources and investment articles every Sunday morning. Grab a coffee and let Owen and the team bring you the best insights.
Here you go: A $50,000 per year passive income special report
Join more 50,000 Australian investors who read our weekly investing newsletter and we’ll send you our passive income investing report right now.
Simply enter your email address and we’ll send it to you. No tricks. Unsubscribe anytime.
Unsubscribe anytime. Read our Terms, Financial Services Guide, Privacy Policy. We’ll never sell your email address. Our company is Australian owned.